BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 23290095)

  • 1. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of venous thromboembolism in patients with cancer.
    Prandoni P
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
    Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
    Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.
    Baser O; Liu X; Phatak H; Wang L; Mardekian J; Kawabata H; Petersel D; Hamilton M; Ramacciotti E
    Am J Ther; 2013; 20(2):132-42. PubMed ID: 23466619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
    Reardon G; Pandya N; Nutescu EA; Lamori J; Damaraju CV; Schein J; Bookhart BK
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):361-72. PubMed ID: 23217529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis against venous thromboembolism in hospitalized medically ill patients.
    Pendergraft T; Liu X; Edelsberg J; Phatak H; Vera-Llonch M; Liu LZ; Oster G
    Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):75-82. PubMed ID: 23300270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.